By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

If you’ve been diagnosed with or are at risk for high cholesterol (meaning you have too much of this waxy substance in your blood), your doctor may recommend a low-cholesterol diet. Learn what a ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...

Rocket Mortgage originates a significant volume of first-time-buyer-friendly FHA loans. It also offers a low-down-payment mortgage and gives qualified buyers help with closing costs.